Brief: Vicore Selects New ATRAG As Next Drug Candidate

Vicore Pharma Holding AB

12/10/2022 07:04

Oct 12 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE SELECTS NEW ATRAG AS NEXT DRUG CANDIDATE
    * C103, AN ANGIOTENSIN II TYPE 2 RECEPTOR (AT2R) AGONIST
(ATRAG),
HAS BEEN SELECTED AS DRUG CANDIDATE
    * COMPOUND HAS A VERY HIGH SELECTIVITY FOR AT2R OVER AT1R
    * PHASE 1 TRIAL IS EXPECTED TO START IN H2-2023

Source text for Eikon:  ID:nWkr2rQpwl 
Further company coverage:  VICOR.ST 
 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))